Market Movers (8-K)
See all →OID
BioAdaptives Inc. announces successful completion of Zeranovia dosage trials, demonstrating significant weight loss with minimal side effects.
Better than expected
OID
8-K: BioAdaptives Bolsters Leadership with Key Appointments to Board of Directors and Advisory Board
BioAdaptives, Inc. announces the appointment of Mark Frissora to its Board of Directors and Reed Harris to its Advisory Board, aiming to leverage their expertise for strategic growth.
OID
BioAdaptives, Inc. has declared a one-for-one stock dividend for all common shareholders, with a record date projected for the second week of January 2025.
OID
BioAdaptives, Inc. has announced the approval of a human clinical trial for its weight management product, Zeranovia, by an Institutional Review Board.
Better than expected
OID
BioAdaptives has completed a 1-for-300 reverse stock split to reduce outstanding shares and increase the stock price, effective November 21, 2024.
OID
BioAdaptives, Inc. disclosed an upcoming reverse stock split after a draft shareholder letter was prematurely released online due to a website error, causing market confusion.
Worse than expected
Quarterly Earnings (10-Q)
See all →OID
BioAdaptives reports a net loss of $111,086 for Q1 2026 while continuing to face substantial doubt regarding its ability to continue as a going concern.
Capital raise
OID
BioAdaptives Inc. reported increased revenue in Q3 2025 driven by new product launches, but also saw a significant rise in net loss and faces substantial doubt about its ability to continue as a going concern.
Delay expected
Worse than expected
Capital raise
OID
BioAdaptives Inc. reported a significant decline in revenue and increased operating expenses, raising substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
OID
BioAdaptives Inc. reports a net loss for Q1 2025, but anticipates revenue growth with upcoming product launches and strategic marketing initiatives.
Worse than expected
Capital raise
OID
BioAdaptives Inc. reported a net loss of $527,373 for the nine months ended September 30, 2024, an increase from the $444,165 loss in the same period of 2023, alongside ongoing concerns about its ability to continue as a going concern.
Worse than expected
Capital raise
OID
BioAdaptives Inc. reports a widened net loss for the second quarter of 2024, impacted by increased operating expenses and cost of revenue, as the company reformulates its product line and explores new market opportunities.
Worse than expected
Capital raise
Annual Reports (10-K)
OID
BioAdaptives, Inc. files its annual 10-K report for the fiscal year ended December 31, 2025, detailing business operations, financial condition, and future outlook.
Worse than expected
Capital raise
OID
BioAdaptives, Inc. reports its 10-K filing for the year ended December 31, 2024, highlighting a strategic shift towards natural health products and medical devices, with new product launches expected in 2025.
Worse than expected
Capital raise
OID
10-K: BioAdaptives Inc. Reports Full Year 2023 Results, Focuses on Growth and Subsidiary Independence
BioAdaptives, Inc. released its 2023 annual report, highlighting a shift towards wholesale distribution and the potential spin-off of its Livestock Impact subsidiary, while navigating financial challenges.
Worse than expected
Capital raise
Insider Trading (Form 4)
See all →OID
Mark P Frissora, a Director of Bioadaptives, Inc., reported a transaction in 15,152 shares of common stock on 2026-08-01-05:00.
OID
Bioadaptives, Inc. reports that Director Mark P. Frissora received Series D Convertible Preferred Stock as compensation for board services.
OID
Director Mark P. Frissora acquired 4,717 shares of Series D Convertible Preferred Stock as compensation for board services.
OID
Bioadaptives, Inc. reports that Director Mark P. Frissora received Series D Convertible Preferred Stock as compensation for board services.
OID
Bioadaptives, Inc. director Mark P. Frissora received Series D Convertible Preferred Stock as compensation for board services.
OID
Bioadaptives Director Mark P. Frissora acquired 2,578 shares of Series D Convertible Preferred Stock as compensation for board services.
Proxy Statements (Def-14A)
OID
BioAdaptives stockholders have approved an amendment to the company's certificate of incorporation to increase the number of authorized common and preferred shares.
Capital raise
OID
BioAdaptives stockholders have approved an amendment to the company's certificate of incorporation to increase the number of authorized common and preferred shares.
Capital raise